ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 1, 2012
Pfizer, Eli Lilly Post Fourth-Quarter Results; Both Score High on Our Valuentum Dividend Cushion
Pfizer and Eli Lilly posted fourth-quarter results with each showing the impact of the industry's "patent cliff." Pfizer has lost exclusivity of Lipitor, while Eli Lilly is now facing competition for its blockbuster drug Zyprexa. Though their respective outlooks remain challenged, the safety of their current dividends remains excellent based on their respective Valuentum Dividend Cushion scores.
Jan 31, 2012
Helmerich & Payne Beats Expectations by $0.17, Beats on Revenues
Our Valuentum Buying Index (VBI) identifies stocks that are undervalued on both a discounted cash-flow basis and relative value basis and that are showing improving technical and momentum indicators. Helmerich & Payne, one of the few firms in our coverage universe that garners a top score on our index, blew by consensus expectations and is showing relative price outperformance today.
Jan 29, 2012
Honeywell Expects Strong 2012 Despite Downturn in Europe During First Half
Honeywell posted strong fourth-quarter results and noted that organic sales and earnings will expand in 2012 despite challenges in Europe. The industrial conglomerate continues to see strength across all four of its business segments.
Jan 29, 2012
Altria Posts Decent Fourth-Quarter Results; Dividend Yield Still Attractive
Altria posted fourth-quarter results that showed the firm retains significant pricing power. The company guided 2012 earnings higher, and we expect Altria's dividend payout to expand this year, offering investors a 6%+ yield at current prices.
Jan 27, 2012
Synaptics Experiencing Relative Strength Today
Synaptics reported better-than-expected fiscal second-quarter earnings yesterday, and the stock is seeing nice relative strength today. We think this interesting firm, known for its Touchpad interface, has further valuation upside.
Jan 27, 2012
P&G Reduces 2012 Outlook; Expects Dividend Increase This Year
Proctor & Gamble issued decent fiscal second-quarter results but its outlook for 2012 was plagued by head winds from currency, taxes, and commodity costs. Still, we think P&G is a core holding in our Dividend Growth portfolio.
Jan 27, 2012
Eastman Chemical Rockets to Over $50 Per Share; Converges to Our Fair Value Estimate
Eastman Chemical, a firm we highlighted as significantly undervalued in our initiation report and November edition of our Best Ideas Newsletter, is surging today on its purchase of Solutia. We like the deal.
Jan 27, 2012
Starbucks is Firing on All Cylinders But Shares Are Expensive
Starbucks put up record fiscal first-quarter results for both revenue and earnings. Though we like the coffee giant's future potential opportunities, its shares are rich at present levels.
Jan 27, 2012
Precision Castparts Issues Fiscal Third-Quarter Results
Precision Castparts' fiscal third-quarter results came in lower than most investors had anticipated. Though we think the metal-bender has valuation upside, we'll be looking to continue to trim our position in the portfolio of our Best Ideas Newsletter.
Jan 26, 2012
3M Issues Fourth-Quarter Results; Reaffirms 2012 Guidance
3M posted a modest increase in fourth-quarter earnings and reaffirmed its 2012 earnings outlook. The firm warned of some weakness in China, Europe, and in its optical film segment during the first half of this year, and we remain on the sidelines based on valuation.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.